Abstract
Objective
The American Thyroid Association (ATA) Pediatric Guidelines recommend selective, prophylactic central neck dissection (pCND) for patients with papillary thyroid carcinoma (PTC) based on tumor focality, tumor size, and the surgeon’s experience. With the expansion of pre-surgical somatic oncogene testing and continued controversy over the benefits of pCND, oncogenic alteration data may provide an opportunity to stratify pCND. This study compared lymph node (LN) involvement in pediatric patients with PTC between tumors with low- and high-invasive-associated alterations to explore the potential utility of preoperative oncogenic alterations in the stratification of pCND.
Methods
This is retrospective cohort study of pediatric patients who underwent somatic oncogene testing post thyroidectomy for PTC between July 2003 and July 2022.
Results
Of 192 eligible PTC patients with postoperative somatic oncogene data, 19 tumors harbored somatic alterations associated with low-invasive disease (19/192, 10%), and 128 tumors harbored a BRAFV600E alteration (45/192, 23%) or an oncogenic fusion (83/192, 43%). Tumors with low-invasive alterations were less likely to present malignant preoperative cytology (2/18, 11%) than those with high-invasive alterations (97/124, 78%; P < 0.001). Twelve patients with low-invasive alterations had LNs dissected from the central neck (12/19, 63%) compared to 127 patients (127/128, 99%) with high-invasive alterations. LN metastasis was identified in two patients with low-invasive alterations (2/19, 11%) compared to 107 patients with high-invasive alterations (107/128, 84%; P < 0.001).
Conclusion
Pediatric patients with low-invasive somatic oncogenic alterations are at low risk for metastasis to central neck LNs. Our findings suggest that preoperative knowledge of somatic oncogene alterations provides objective data to stratify pediatric patients who may not benefit from pCND.
Graphical abstract
Introduction
Papillary thyroid carcinoma (PTC) is the most common pediatric endocrine malignancy. While long-term disease-specific survival approaches 100% for children and adolescents (1, 2), recurrence following treatment may affect up to 30% of patients (3, 4), with cervical lymph node metastasis (LNM) in central and lateral neck compartments being well-established sites of persistent and recurrent disease. The 2015 American Thyroid Association (ATA) Pediatric Guidelines recommend selective consideration of prophylactic central neck dissection (pCND) for patients with PTC based upon tumor focality, tumor size, and the experience of the surgeon (Recommendation 12B) (5). This recommendation was based on data demonstrating a high rate of metastasis (30–90%) (6, 7) to regional lymph nodes (LNs) in the pediatric population and was used to stratify patients into ATA risk levels for selective use of radioiodine therapy (RAIT; Recommendation 15) (5, 8, 9). In addition, the extent of initial LN resection has been shown to impact disease free survival (DFS) (1, 5, 10). However, it is important to consider the potential benefit of pCND against the increased risk of surgical complications (11, 12). Based on this, the recent 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma (DTC) recommended limiting pCND to patients with ‘suspicious features of advanced thyroid cancer’ (13).
Pre-operative assessment for surgical stratification commonly includes ultrasound (US) and fine needle aspiration (FNA), but these are highly subjective measures with wide variability in completeness and interpretation across institutions (14, 15, 16). Identifying a more objective preoperative marker that could predict the invasive behavior of the tumor, particularly tumors unlikely to metastasize to central neck LNs, would be clinically useful in decreasing reliance on pCND. If proven reliable, this marker would be associated with a high likelihood of surgical remission without placing patients at increased risk for potential surgical complications associated with pCND.
With the expansion of somatic oncogene analysis using next-generation sequencing (NGS), and data confirming associations between oncogenic alterations and invasive tumor behavior (17), knowledge of the somatic alteration preoperatively has the potential to further inform the surgical management of pediatric PTC (17, 18, 19, 20). Oncogene test results are not subject to variability in provider interpretation and offer impartial foresight into the pathological subtype and metastatic behavior of a patient’s disease (17, 21). This study was undertaken to compare LN involvement in pediatric patients with PTC demonstrating low- and high-invasive associated alterations to assess the association between molecular subtype and N1 disease in an effort to determine if somatic oncogene testing could be used to guide pCND stratification.
Methods
Data collection
An IRB-approved study was conducted on patients with PTC <19 years old who underwent thyroid surgery and somatic oncogene testing at the Children’s Hospital of Philadelphia (CHOP) between July 2003 and July 2022. Patient demographics, medical history, thyroid US, cytology, surgical approach, pathologic features, diagnosis, and postoperative somatic oncogene findings were extracted from the hospital electronic medical record system (Epic®). FNA cytology was classified according to The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) (22). A two-stage thyroidectomy was defined as a lobectomy followed by a completion thyroidectomy. Prophylactic CND (level VI or levels VI–VII) was performed for patients undergoing thyroidectomy without preoperative US evidence of central neck LN metastasis (American Joint Committee on Cancer (AJCC) N0a) and selected patients undergoing lobectomy with indeterminate (TBSRTC III–V) or malignant (TBSRTC VI) cytology. A therapeutic CND was performed for patients with preoperative evidence and FNA confirmation of central and lateral neck LN metastasis (AJCC N1b).
After surgery, primary tumor (T), regional LNs (N), and distant metastasis (M) were assigned using the 8th edition of the AJCC classification for PTC (23). Thyroid cancer risk stratification was adopted from the 2015 ATA Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Carcinoma (5). Data analyses were limited to patients with a histological diagnosis of PTC.
Molecular genetic analyses
Sequential somatic oncogene testing was performed on all tumors based on a histological diagnosis of PTC without selection based on AJCC TNM. Differing somatic panels were used over the length of the study based on availability and changes in clinical practice. Somatic alterations were identified using the following targeted assays: (i) CHOP’s Comprehensive Solid Tumor Panel (CSTP), (ii) Asuragen miRInform thyroid test, or (iii) Qiagen BRAF amplification test. CSTP comprises 238 genes and more than 600 fusions to detect single nucleotide variants, indels, gene fusions, and copy number alterations in pathologic specimens (24, 25). The Asuragen miRInform thyroid test analyzes the presence of common variants in BRAF, HRAS, KRAS, and NRAS, and fusion transcripts in RET/PTC1, RET/PTC3,and PAX8-PPARγ in pathologic specimens, and does not analyze PTEN, DICER1, NTRK fusions, and novel RET fusions (26). Qiagen detects somatic mutations in the BRAF oncogene utilizing RT-PCR (27).
Statistical analysis
Genetic alterations were classified into two groups in accordance with previous studies demonstrating genotypic variations in behavior of pediatric PTC: low-invasive alterations (DICER1, PTEN, RAS, and TSHR variants, BRAF non-V600E variants; and PAX8–PPARγ fusion) and high-invasive alterations (RET, NTRK, ALK, BRAF, or MET fusions and BRAFV600E variant) (17, 18, 28, 29, 30). Patients with germline mutations in thyroid cancer predisposition syndromes, such as PTEN Hamartoma Tumor Syndrome and DICER1 syndrome, were excluded from the analysis. Preoperative features, clinicopathologic characteristics, and outcomes were compared between patients with low- and high-invasive alterations. Categorical variables were summarized using frequency (percent) and were compared using the two-tailed Fisher exact test. Continuous variables were summarized using median (IQR = 1st–3rd quartiles) and were compared by Mann–Whitney U test (nonparametric). P-values ≤0.05 were considered statistically significant. All statistical analyses were performed in R 4.1.0 and R Studio 1.4.1717 with packages tidyverse and rstatix (31, 32, 33).
Results
Study cohort
A database of 192 pediatric PTC patients with postoperative somatic oncogene testing at CHOP was queried. Of the 192 eligible patients, 147 (147/192, 77%) patients had pathogenic/likely pathogenic (P/LP) somatic oncogenic alterations detected. Nineteen patients demonstrated P/LP somatic alterations associated with low-invasive disease (19/192, 10%), while 128 patients possessed somatic alterations associated with high-invasive disease (128/192, 67%), including BRAFV600E (45/192, 23%) and RET, NTRK, ALK, BRAF,or MET fusions (83/192, 43%; Table 1). The remaining 45 eligible patients were either found to not carry a somatic oncogenic alteration (40/192, 21%), harbor less frequent P/LP oncogenic alterations (3/192, 2%), including RAD50, CHEK2,or BLM, or carry germline variants (2/192, 1%). Of the 40 patients with no identifiable driver thyroid oncogenic alteration, 43% (17/40) underwent research molecular testing using the Asuragen miRinform Thyroid Test, which is not an NGS panel and does not test for fusion partners. These 17 samples were not available for retesting. The other 58% (23/40) underwent molecular testing using CSTP, but no variants/fusions were found.
Demographics and medical history of pediatric patients with papillary thyroid carcinoma and somatic driver alterations confirmed by postoperative oncogene testing. Data are presented as n (%).
| Characteristics | Values |
|---|---|
| Demographics | |
| Sex | |
| Male | 38 (25.9) |
| Female | 109 (74.1) |
| Race/ethnicity | |
| Asian | 11 (7.5) |
| Black or African American | 6 (4.1) |
| Hispanic or Latino | 20 (13.6) |
| White | 105 (71.4) |
| Other | 9 (6.1) |
| Unknown/not reported | 9 (6.1) |
| Medical history | |
| Radiotherapy for primary malignancy | |
| Yes | 9 (6.1) |
| No | 136 (92.5) |
| Unknown/not reported | 2 (1.4) |
| Prior thyroid disease | |
| Yes | 41 (27.9) |
| No | 106 (72.1) |
| Family member with thyroid cancer | |
| Yes | 21 (14.3) |
| No | 122 (83.0) |
| Unknown/not reported | 4 (2.7) |
| Next-generation sequencing panel | |
| Comprehensive solid tumor panel | 123 (83.7) |
| Asuragen miRinform thyroid test | 22 (15.0) |
| Qiagen amplification test | 2 (1.4) |
| Driver alteration | |
| Low-invasive | |
| BRAF nonV600E varianta | 2 (1.4) |
| DICER1 variant | 3 (2.0) |
| PAX8–PPARγ fusion | 2 (1.4) |
| PTEN variant | 1 (0.7) |
| RAS variant | 8 (5.4) |
| TSHR variant | 3 (2.0) |
| High-invasive | |
| ALK fusion | 8 (5.4) |
| BRAF fusion | 5 (3.4) |
| BRAFV600E variant | 45 (30.6) |
| MET fusion | 4 (2.7) |
| NTRK fusion | 24 (16.3) |
| RET fusion | 42 (28.6) |
aT599del and V600_K601delinsE.
Preoperative, cytologic, and histologic features
Clinicopathologic features of the 147 patients with somatic oncogenic alterations are presented in Table 2 and Fig. 1. Patients with low-invasive alterations were less likely to demonstrate lymphadenopathy on preoperative ultrasound imaging (1/19, 5%) compared to patients with high-invasive alterations (70/128, 55%; P < 0.001). Similarly, tumors with low-invasive alterations were less likely to present malignant preoperative cytology (TBSRTC VI; 2/18, 11%) than those with high-invasive alterations (97/124, 78%; P < 0.001). The majority of patients (15/18, 83%) with low-invasive alterations who underwent FNA demonstrated indeterminate cytology (TBSRTC III–V). Of the nine lesions with high-invasive alterations having Bethesda III and IV cytology, 56% (5/9) had LN metastasis. Approximately 37% (7/19) of patients with low-invasive alterations underwent lobectomy or two-stage thyroidectomy, while 95% (121/128) of patients with high-invasive alterations underwent total thyroidectomy (Table 2).
Clinicopathologic features of 19 patients with low-invasive and 128 patients with high-invasive somatic driver alterations who underwent thyroidectomy. Characteristics include age at the time of surgery, sex, preoperative lymphadenopathy, cytology (TBSRTC), histologic subtype, primary tumor (T) staging, regional lymph node (N) staging, distant metastasis (M) staging, ATA risk status, radioactive iodine (RAI) therapy, lymphatic invasion, and response to therapy at 1 year post initial treatment. Genetic alterations were categorized by driver. ATA, American Thyroid Association; CSTP, Comprehensive Solid Tumor Panel; PTC, Papillary Thyroid Carcinoma; TBSRTC, The Bethesda System for Reporting Thyroid Cytopathology.
Citation: European Thyroid Journal 13, 4; 10.1530/ETJ-23-0265
Clinicopathologic characteristics of pediatric patients with papillary thyroid carcinoma stratified by risk of driver alteration. Data are presented as n (%).
| Total, n = 147 | Driver alteration | P | ||
|---|---|---|---|---|
| Low-invasive, n = 19 | High-invasive, n = 128 | |||
| Preoperative lymphadenopathya | ||||
| Present | 71 (48.3) | 1 (5.3) | 70 (54.7) | <0.001 |
| Absent | 71 (48.3) | 17 (89.5) | 54 (42.2) | |
| Unknown/not reported | 5 (3.4) | 1 (5.3) | 4 (3.1) | |
| FNA performedb | ||||
| Benign (II) | 3 (2.0) | 1 (5.3) | 2 (1.6) | <0.001 |
| AUS (III) | 6 (4.1) | 2 (10.5) | 4 (3.1) | |
| Follicular neoplasm (IV) | 12 (8.2) | 7 (36.8) | 5 (3.9) | |
| Suspicious for malignancy (V) | 22 (15.0) | 6 (4.1) | 16 (12.5) | |
| Malignant (VI) | 99 (67.3) | 2 (10.5) | 97 (75.8) | |
| Not performed | 4 (2.7) | 1 (5.3) | 3 (2.3) | |
| Unknown/not reported | 1 (0.7) | 0 (0.0) | 1 (0.8) | |
| Age at time of thyroid surgery, yearsc | 14.7 (12.9–16.8) | 14.6 (14.2–15.8) | 14.7 (12.9–16.9) | 0.968 |
| Surgery type | ||||
| Total thyroidectomy | 133 (90.5) | 12 (63.2) | 121 (94.5) | <0.001 |
| Lobectomy/isthmectomy | 14 (9.5) | 7 (36.8) | 7 (5.5) | |
| Completion | 8 (5.4) | 3 (15.8) | 5 (3.9) | |
| PTC histologic subtype | ||||
| Classic PTC | 83 (56.5) | 3 (15.8) | 80 (62.5) | <0.001 |
| Diffuse sclerosing variant PTC | 16 (10.9) | 0 (0.0) | 16 (12.5) | |
| Follicular variant PTC | 24 (16.3) | 10 (52.6) | 14 (10.9) | |
| Mixed PTC | 12 (8.2) | 4 (21.1) | 8 (6.3) | |
| Oncocytic PTC | 2 (1.4) | 1 (5.3) | 1 (0.8) | |
| Solid variant PTC | 3 (2.0) | 0 (0.0) | 3 (2.3) | |
| Tall cell variant PTC | 2 (1.4) | 0 (0.0) | 2 (1.6) | |
| Warthin-like PTC | 1 (0.7) | 0 (0.0) | 1 (0.8) | |
| Not specified | 4 (2.7) | 1 (5.3) | 3 (2.3) | |
aPreoperative lymphadenopathy was determined through a review of thyroid ultrasound images and/or physical examination findings; bFNA was classified according to the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). The highest category on primary tumor and/or lymph node(s) is reported. The proportion of malignant cytology was compared with two-tailed Fisher exact test; cValues are median (IQR).
AUS, atypia of undetermined significance; FNA, fine needle aspiration; IQR, interquartile range (25th–75th percentile); PTC, papillary thyroid carcinoma.
Tumors with low-invasive alterations were more likely to be associated with low-invasive pathologic features and PTC subtypes associated with a lower risk for LN metastasis (34, 35). Of the patients with low-invasive alterations, 47% (9/19) were diagnosed with encapsulated-follicular variant PTC (enc-fvPTC). More than half of the patients (80/128, 63%) harboring high-invasive alterations demonstrated classic variant PTC (cPTC). Tumors harboring low-invasive alterations were significantly less likely to demonstrate multifocal disease (P = 0.008), bilateral disease (P = 0.010), extrathyroidal extension (P = 0.020), lymphatic invasion (P < 0.001), and extranodal extension (P < 0.001) compared to tumors with high-invasive alterations. No significant difference in vascular invasion (P = 0.916) was identified between the two cohorts (Table 3).
Postoperative characteristics of pediatric patients with papillary thyroid carcinoma stratified by risk of driver alteration. Data are presented as n (%).
| Total, n = 147 | Driver alteration | P | ||
|---|---|---|---|---|
| Low-invasive, n = 19 | High-invasive, n = 128 | |||
| AJCC TNM classificationa | ||||
| Primary tumor (T) | ||||
| T1 | 63 (42.9) | 6 (31.6) | 57 (44.5) | 0.147 |
| T1a | 22 (15.0) | 3 (15.8) | 19 (14.8) | |
| T1b | 41 (27.9) | 3 (15.8) | 38 (29.7) | |
| T2 | 36 (24.5) | 9 (47.4) | 27 (21.1) | |
| T3 | 35 (23.8) | 4 (21.1) | 31 (24.2) | |
| T3a | 21 (14.3) | 4 (21.1) | 17 (13.3) | |
| T3b | 14 (9.5) | 0 (0.0) | 14 (10.9) | |
| T4a | 12 (8.2) | 0 (0.0) | 12 (9.4) | |
| TX | 1 (0.7) | 0 (0.0) | 1 (0.8) | |
| Regional lymph nodes (N) | ||||
| N0 | 38 (25.9) | 17 (89.5) | 21 (16.4) | <0.001 |
| N0a | 30 (20.4) | 10 (52.6) | 20 (15.6) | |
| N0b | 8 (5.4) | 7 (36.8) | 1 (0.8) | |
| N1 | 109 (74.1) | 2 (10.5) | 107 (83.6) | |
| N1a | 43 (29.3) | 1 (5.3) | 42 (32.8) | |
| N1b | 66 (44.9) | 1 (5.3) | 65 (50.8) | |
| Distant metastasis (M) | ||||
| M0 | 113 (76.9) | 17 (89.5) | 96 (75.0) | 0.140 |
| M1 | 30 (20.4) | 1 (5.3) | 29 (22.7) | |
| Lungs | 27 (18.4) | 1 (5.3) | 26 (20.3) | |
| Bone | 2 (1.4) | 0 (0.0) | 2 (1.6) | |
| Brain | 1 (0.7) | 0 (0.0) | 1 (0.8) | |
| Chest | 1 (0.7) | 0 (0.0) | 1 (0.8) | |
| MX | 4 (2.7) | 1 (5.3) | 3 (2.3) | |
| Tumor characteristics | ||||
| Focality | ||||
| Unifocal | 63 (42.9) | 14 (73.7) | 49 (38.3) | 0.008 |
| Multifocal | 83 (56.5) | 5 (26.3) | 78 (60.9) | |
| Unknown/not reported | 1 (0.7) | 0 (0.0) | 1 (0.8) | |
| Laterality | ||||
| Unilateral | 83 (56.5) | 15 (78.9) | 68 (53.1) | 0.010 |
| Bilateral | 63 (42.9) | 4 (21.1) | 59 (46.1) | |
| Unknown/not reported | 1 (0.7) | 0 (0.0) | 1 (0.8) | |
| Extrathyroidal extension | ||||
| Present | 55 (37.4) | 2 (10.5) | 53 (41.4) | 0.020 |
| Microscopic | 28 (19.0) | 2 (10.5) | 26 (20.3) | |
| Gross | 27 (18.4) | 0 (0.0) | 27 (21.1) | |
| Absent | 85 (57.8) | 16 (84.2) | 69 (53.9) | |
| Unknown/not reported | 7 (4.8) | 1 (5.3) | 6 (4.7) | |
| Vascular invasion | ||||
| Present | 58 (39.5) | 7 (36.8) | 51 (39.8) | 0.916 |
| Absent | 83 (56.5) | 11 (57.9) | 72 (56.3) | |
| Unknown/not reported | 6 (4.1) | 1 (5.3) | 5 (3.9) | |
| Lymphatic invasion | ||||
| Present | 106 (72.1) | 3 (15.8) | 103 (80.5) | <0.001 |
| Absent | 35 (23.8) | 15 (78.9) | 20 (15.6) | |
| Unknown/not reported | 6 (4.1) | 1 (5.3) | 5 (3.9) | |
| Extranodal extension | ||||
| Present | 55 (37.4) | 0 (0.0) | 55 (43.0) | <0.001 |
| Absent | 77 (52.4) | 18 (94.7) | 59 (46.1) | |
| Unknown/not reported | 15 (10.2) | 1 (5.3) | 14 (10.9) | |
| 131I RAIT | ||||
| Received 131I RAIT | ||||
| Yes | 114 (77.6) | 8 (42.1) | 106 (82.8) | <0.001 |
| No | 32 (21.8) | 11 (57.9) | 21 (16.4) | |
| Unknown/not reported | 1 (0.7) | 0 (0.0) | 1 (0.8) | |
| Cumulative RAIT dosage, mCib | 103 (77–144) | 104 (75–125) | 103 (78–148) | 0.968 |
| ATA cancer risk stratificationc | ||||
| Low risk | 52 (35.4) | 16 (84.2) | 36 (28.1) | <0.001 |
| Intermediate risk | 41 (27.9) | 2 (10.5) | 39 (30.5) | |
| High risk | 54 (36.7) | 1 (5.3) | 53 (41.4) | |
aTNM was adopted from the AJCC 8 Edition Staging and evaluated within 12 months post-initial surgery; bValues are median (IQR); cThyroid cancer risk stratification was adopted from the ‘2015 ATA Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer’ and evaluated at initial surgery. Extensive involvement was defined as >5 positive lymph nodes.
ATA, American Thyroid Association; AJCC, American Joint Committee on Cancer; IQR, interquartile range (25th–75th percentile); RAIT, radioactive iodine therapy; TNM, tumor–node–metastasis.
Cervical lymph node involvement and distant metastasis
Patients with low-invasive alterations were less likely to have LNs removed from the central and/or lateral neck compared to patients with high-invasive alterations. Twelve patients (12/19, 63%) with low-invasive alterations had LNs dissected from the central neck compartment compared to 127 patients (127/128, 99%) with high-invasive alterations (P < 0.001). Of the low-invasive cohort of patients, 58% (11/19) underwent pCND, for which 91% (10/11) demonstrated no evidence of regional LN metastasis (AJCC N0a disease). One patient (1/19; 5%) had a therapeutic CND, and seven patients (7/19; 37%) did not undergo CND. Of the high-invasive cohort of patients, 36% (46/128) underwent a pCND, 60% (77/128) had therapeutic CND, and 4% (5/128) did not have a CND.
Patients with high-invasive alterations had a greater number of central neck LNs dissected than patients with low-invasive alterations, reporting a median of 14 LNs (IQR = 8–20) removed from patients with high-invasive alterations and a median of 6 LNs (IQR = 3–8) removed from patients with low-invasive alterations (P = 0.001; Table 4). Comparably, one patient (1/19; 5%) with a low-invasive alteration had LNs dissected from the lateral neck compartment compared to 73 patients (73/128, 57%) with high-invasive alterations (P < 0.001).
Lymph node involvement in pediatric patients with papillary thyroid carcinoma stratified by risk of diver alteration. Data are presented as n (%) or as median (IQR).
| Total, n = 147 | Driver alteration | P | ||
|---|---|---|---|---|
| Low-invasivea, n = 19 | High-invasive, n = 128 | |||
| CND | ||||
| Prophylactic | 57 (38.8) | 11 (57.9) | 46 (35.9) | <0.001 |
| Therapeutic | 78 (53.1) | 1 (5.3) | 77 (60.1) | |
| Not performed | 12 (8.2) | 7 (36.8) | 5 (3.9) | |
| Location of LN removalb | ||||
| Central compartment (levels VI–VII) | ||||
| Yes | 139 (9.5) | 12 (63.2) | 127 (99.2) | <0.001 |
| No | 8 (5.4) | 7 (36.8) | 1 (0.8) | |
| Lateral compartment (levels II–V) | ||||
| Yes | 74 (50.3) | 1 (5.3) | 73 (57.0) | <0.001 |
| No | 73 (49.7) | 18 (94.7) | 55 (43.0) | |
| Number of LNs removedb | ||||
| Total (levels II–VII) | ||||
| Positive | 8 (1–20) | 0 (0–0) | 9 (2–22) | <0.001 |
| Total | 24 (11–49) | 7 (3–9) | 25 (13–52) | <0.001 |
| Positive/total ratio | 0.34 | 0.00 | 0.34 | <0.001 |
| Central compartment (levels VI–VII) | ||||
| Positive | 6 (1–11) | 0 (0–0) | 6 (1–12) | <0.001 |
| Total | 13 (8–20) | 6 (3–8) | 14 (8–20) | 0.001 |
| Positive/total ratio | 0.42 | 0.00 | 0.43 | <0.001 |
| Lateral compartment (levels II–V) | ||||
| Positive | 7 (3–13) | 1 (1–1) | 7 (4–13) | <0.001 |
| Total | 31 (16–47) | 16 (16–16) | 32 (17–47) | <0.001 |
| Positive/total ratio | 0.23 | 0.06 | 0.22 | <0.001 |
IQR, interquartile range (25th–75th percentile); LN, lymph node, pCND, prophylactic central neck dissection.
aOne patient with a low-invasive PAX8–PPARγ fusion underwent a CND and selective removal of two LNs. Operative and pathology records report no metastatic LNs, however the total number of LNs removed was not reported and hence excluded from the quantitative analysis.
bpCND was indicated for patients having (i) no lymphadenopathy on preoperative ultrasound and/or physical examination by provider and/or (ii) FNA confirmation of benign LNs. Therapeutic LN dissection was indicated for patients having (i) central neck lymphadenopathy on preoperative ultrasound with FNA confirmation of malignancy or (ii) lateral neck lymphadenopathy on preoperative ultrasound with FNA confirmation of malignancy or (iii) preoperative ultrasound demonstrating rounded, echogenic LNs with peripheral blood flow along with an invasive-appearing lesion inside the thyroid with FNA confirmation of being suspicious for malignancy or malignant.
IQR, interquartile range (25th–75th percentile); LN, lymph node, pCND, prophylactic central neck dissection.
Overall, 84% (107/128) of patients with high-invasive alterations demonstrated metastatic LNs (N1a/N1b), compared to 11% (2/19) of patients with low-invasive alterations (P < 0.001; Table 3). Of the 42 patients (42/128; 33%) with N1a disease in the high-invasive cohort, 29 (29/42; 69%) did not have pre-operative lymphadenopathy identified on ultrasound and/or physical exam. Only two patients with low-invasive alterations (BRAFT599del; TSHRM453T ) had positive metastatic LNs: 8/11 LNs+ (N1a) and 3/19 LN+ (N1b), respectively. Lymphadenopathy was identified preoperatively and confirmed on surgical pathology for the patient with TSHRM453T . Evaluation of LNs was limited preoperatively for the patient with BRAFT599del , the only patient in the low-invasive cohort found to have N1a disease despite negative preoperative US.
Twenty-nine patients (29/128; 23%) with high-invasive alterations demonstrated distant metastasis. Sites of distant metastasis in the high-invasive cohort included the lungs (26/128, 20%), bones (2/128, 2%), brain (1/128, 1%), and/or mediastinum (1/128, 1%). These tumors harbored RET fusions (14/29; 48%), NTRK fusions (9/29; 31%), ALK fusions (3/29; 10%), BRAFV600E (2/29; 7%), or MET fusion (1/29, 3%). By contrast, mild diffuse activity in the lungs was identified on a post-radiotherapy scan for one patient with a low-invasive NRASQ61R variant. Pathological examination revealed an encapsulated, multifocal, and bilateral fvPTC with lymphatic and vascular invasion, which was subsequently staged as T2N0bM1. This patient did not have tissue available to assess for a combined RAS-EIF1AX variant, which may be associated with more invasive disease in adult patients (36).
Based upon the ATA pediatric PTC risk stratification, 84% (16/19) of patients with low-invasive alterations demonstrated ATA low-risk thyroid cancer, compared to 28% (36/128) of patients with high-invasive alterations (P < 0.001). Fifty-three patients (53/128; 41%) harboring high-invasive alterations demonstrated PTC classified as ATA high-risk.
Discussion
We evaluated LN involvement in 147 pediatric PTC patients who demonstrated somatic oncogenic alterations over a 19-year study period. Our data support previous studies reporting that invasive tumor behavior, particularly the metastatic potential to regional LNs, correlates with somatic oncogenic alterations (19, 22). In the current study, only 11% (2/19) of PTC patients with low-invasive somatic oncogenic alterations demonstrated N1 disease, compared to 84% (107/128) of patients with high-invasive oncogenic alterations (P < 0.001; Table 3). Overall, 84% (16/19) of PTC patients harboring low-invasive alterations were categorized as ATA low-risk for persistent/recurrent disease, while 72% (92/128) of patients with high-invasive alterations (BRAFV600E and RET, NTRK, ALK, BRAF, or MET fusions) were categorized as ATA intermediate- or high-risk for persistent/recurrent disease (Table 3).
Forty-six patients (46/128; 36%) had a pCND in the high-invasive cohort. Of these patients, 61% (28/46) had LNM and no pre-operative evidence of central neck LN disease on pre-operative US, demonstrating oncogene analysis adds information about the metastatic potential that US and physical examination may miss. Furthermore, in nine patients with indeterminate cytology (Bethesda III or IV) and detection of a high-invasive oncogene, five patients (5/9, 56%) were found to have LNM – 60% (3/5) with N1a disease found on pCND and 40% (2/5) with N1b disease. Thus, pre-operative identification of an oncogene may be used to stratify which patients with indeterminate cytology may benefit from pCND. Of the 11 patients with pCND in the low-invasive cohort, 91% (10/11) were found to have no LN metastasis (N0a disease), showing there is potential to stratify patients out of the pCND category using somatic oncogene analysis.
Our observations are aligned with previous pediatric (17, 37, 38) and adult (39, 40, 41) studies evaluating the applicability of molecular oncogenic alteration classification to predict invasive behavior of PTC. While the Thyroid Cancer Genome Atlas (21) and other reports (39) have grouped PTC into RAS-like and BRAF-like oncogenic driver groups for low- and high-invasive behavior in adult PTC, pediatric-specific somatic oncogene analysis suggests that a three-tiered system more accurately describes increasing risk of invasive behavior: (i) RAS-like oncogenes (PTEN, DICER1, RAS,and PAX8–PPARγ) are associated with a low risk for LNM; (ii) BRAFV600E is associated with a high risk for regional (N1) LNM; and (iii) fusion oncogenes (RET, NTRK, ALK, BRAF, or MET fusions) are associated with a high risk for regional (N1) and distant (M1) metastasis (17, 21, 39).
The results of our study hold potential clinical applicability as discussion remains over the benefit of pCND in the initial approach to management of pediatric patients with PTC. The 2015 ATA Pediatric Guidelines (5), as well as several recent publications (42, 43), rely on N status to stratify the extent of initial surgery (43) and RAIT (5, 42). There are, however, concerns over increased surgical complications associated with pCND (12), with the recent European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma recommending to limit pCND to patients with ‘suspicious features of advanced thyroid cancer’ (13). Preoperative cytopathology may aid in patient selection, limiting pCND to patients with TBSRTC V and VI cytology (20). However, the invasive behavior of PTC, including sonographic assessment of LN disease and cytological classification, is subjective with wide variation across institutions limiting the ability to make generalized recommendations based solely on US and cytology (15). The incorporation of somatic oncogene testing into the preoperative assessment may afford an opportunity to limit pCND for patients with nodules harboring low-invasive somatic alterations that demonstrate low-risk features on preoperative ultrasound (i.e. smooth margins and wider-than-tall shape and no evidence of extrathyroidal extension, punctate echogenic foci, or regional adenopathy (N0b status)) and TBSRTC indeterminate cytology (categories III/atypia of undetermined significance and IV/follicular neoplasm) (20).
The limitations of this study are its single-center retrospective design, variance in somatic oncogenic panels, a lower percentage of patients with low-invasive alterations undergoing CND compared to patients with high-invasive alterations, and lack of somatic oncogene data for all tumors. Despite these limitations, the data on the lower rate of central neck LNM in tumors with low-invasive somatic oncogenic alterations are intriguing (Table 4) and support the potential benefit of prospective studies exploring the utility of preoperative molecular testing to stratify surgical approach to care.
Current efforts are underway to increase the sample size and perform multi-omics analysis to further delineate the genomic landscape of pediatric PTC beyond somatic oncogene driver. One of the goals of this initiative is to identify additional markers of invasive behavior for the 16% (21/128) of tumors that were found to have a high-invasive somatic alteration but did not have metastasis to the central neck compartment (N0; Table 3). Prospective, multi-center studies are warranted to confirm whether the incorporation of all available data, including ultrasonography, cytology, and somatic oncogene, can be incorporated into clinical practice in an effort to reduce potential surgical complications of pCND without compromising the ability to stratify RAIT based on current pediatric risk stratification systems or to achieve remission from disease (5, 42). To this end, the authors have helped create the Child and Adolescent Thyroid Consortium (CATC), an international pediatric thyroid consortium designed to enhance collaboration between multidisciplinary pediatric thyroid centers (www.thyroidcatc.org).
Conclusion
Pediatric patients with low-invasive somatic oncogenic alterations are at low-risk for metastasis to central neck LNs. Our findings suggest that preoperative knowledge of somatic oncogene alterations provides objective data to stratify pediatric patients who may not benefit from pCND. Future prospective studies are needed to validate if comprehensive somatic NGS panels for pediatric patients with indeterminate cytology can be used to optimize surgical management, limiting pCND to tumors with high-invasive somatic variants and fusions and not performing pCND for tumors with low-invasive alterations.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the study reported.
Funding
This work was supported in part by The Children’s Hospital of Philadelphia Frontier Program (grant no. 000000495).
Ethics
This retrospective study involving human subjects was reviewed and approved by the Children’s Hospital of Philadelphia Institutional Review Board (CHOP IRB #17-014224). Written informed consent from the participant and/or participant’s legal guardian was not required per CHOP IRB; a waiver of consent/parental permission has been approved per 45 CRF 46.116(d).
Author contribution statement
AJB devised the project. JAB, MB, AI, and SH collected the data and performed the analysis. JAB, JCRF, and SH created the tables and figures. JAB and MB wrote the manuscript, with support and critical review provided by SH, AJB, JCRF, AI, MB, AF, KK, NSA, and SMM. All authors discussed the results and provided editorial review of the manuscript.
References
- 1↑
Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, & Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World Journal of Surgery 2010 34 1192–1202. (https://doi.org/10.1007/s00268-009-0364-0)
- 2↑
Golpanian S, Perez EA, Tashiro J, Lew JI, Sola JE, & Hogan AR. Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients. Pediatric Surgery International 2016 32 201–208. (https://doi.org/10.1007/s00383-015-3855-0)
- 3↑
Wang X, & Wang XL. Prognostic analysis of recurrence in children and adolescents with differentiated thyroid cancer. Chinese Medical Journal 2020 133 2281–2286. (https://doi.org/10.1097/CM9.0000000000000910)
- 4↑
Rubinstein JC, Herrick-Reynolds K, Dinauer C, Morotti R, Solomon D, Callender GG, & Christison-Lagay ER. Recurrence and complications in pediatric and adolescent papillary thyroid cancer in a high-volume practice. Journal of Surgical Research 2020 249 58–66. (https://doi.org/10.1016/j.jss.2019.12.002)
- 5↑
Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, Dinauer CA, Hamilton J, Hay ID, Luster M, et al.Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 2015 25 716–759. (https://doi.org/10.1089/thy.2014.0460)
- 6↑
Al-Qurayshi Z, Hauch A, Srivastav S, Aslam R, Friedlander P, & Kandil E. A national perspective of the risk, presentation, and outcomes of pediatric thyroid cancer. JAMA Otolaryngology – Head and Neck Surgery 2016 142 472–478. (https://doi.org/10.1001/jamaoto.2016.0104)
- 7↑
Luster M, Lassmann M, Freudenberg LS, & Reiners C. Thyroid cancer in childhood: management strategy, including dosimetry and long-term results. Hormones 2007 6 269–278. (https://doi.org/10.14310/horm.2002.1111023)
- 8↑
Glover AR, Gundara JS, Norlen O, Lee JC, & Sidhu SB. The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma. Gland Surgery 2013 2 196–205. (https://doi.org/10.3978/j.issn.2227-684X.2013.10.05)
- 9↑
Hughes DT, Rosen JE, Evans DB, Grubbs E, Wang TS, & Solórzano CC. Prophylactic central compartment neck dissection in papillary thyroid cancer and effect on locoregional recurrence. Annals of Surgical Oncology 2018 25 2526–2534. (https://doi.org/10.1245/s10434-018-6528-0)
- 10↑
Ngo DQ, Le DT, & Le Q. Prophylactic central neck dissection to improve disease-free survival in pediatric papillary thyroid cancer. Frontiers in Oncology 2022 12 935294. (https://doi.org/10.3389/fonc.2022.935294)
- 11↑
Scholfield DW, Lopez J, Badillo ND, Eagan A, Levyn H, LaQuaglia M, Shaha AR, Shah JP, Wong RJ, Patel SG, et al. Complications of thyroid cancer surgery in pediatric patients at a tertiary cancer center. Annals of Surgical Oncology 2023 30 7781–7788. (https://doi.org/10.1245/s10434-023-14079-x)
- 12↑
Machens A, Elwerr M, Thanh PN, Lorenz K, Schneider R, & Dralle H. Impact of central node dissection on postoperative morbidity in pediatric patients with suspected or proven thyroid cancer. Surgery 2016 160 484–492. (https://doi.org/10.1016/j.surg.2016.03.007)
- 13↑
Lebbink CA, Links TP, Czarniecka A, Dias RP, Elisei R, Izatt L, Krude H, Lorenz K, Luster M, Newbold K, et al.2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. European Thyroid Journal 2022 11. (https://doi.org/10.1530/ETJ-22-0146)
- 14↑
Terzi NK, & Terzi T. Thyroid fine-needle aspiration cytology: malignancy rate in the category of indeterminate significant atypia/indeterminate significant follicular lesion. Annals of Saudi Medicine 2024 44 31–38. (https://doi.org/10.5144/0256-4947.2024.31)
- 15↑
Padmanabhan V, Marshall CB, Akdas Barkan G, Ghofrani M, Laser A, Tolgay Ocal I, David Sturgis C, Souers R, & Kurtycz DFI. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists. Diagnostic Cytopathology 2017 45 399–405. (https://doi.org/10.1002/dc.23681)
- 16↑
Jia MR, Baran JA, Bauer AJ, Isaza A, Surrey LF, Bhatti T, McGrath C, Jalaly J, Mostoufi-Moab S, Adzick NS, et al. Utility of fine-needle aspirations to diagnose pediatric thyroid nodules. Hormone Research in Paediatrics 2021 94 263–274. (https://doi.org/10.1159/000519307)
- 17↑
Franco AT, Ricarte-Filho JC, Isaza A, Jones Z, Jain N, Mostoufi-Moab S, Surrey L, Laetsch TW, Li MM, DeHart JC, et al.Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers. Journal of Clinical Oncology 2022 40 1081–1090. (https://doi.org/10.1200/JCO.21.01861)
- 18↑
Pekova B, Sykorova V, Dvorakova S, Vaclavikova E, Moravcova J, Katra R, Astl J, Vlcek P, Kodetova D, Vcelak J, et al.RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas. Thyroid 2020 30 1771–1780. (https://doi.org/10.1089/thy.2019.0802)
- 19↑
Mitsutake N, & Saenko V. Molecular pathogenesis of pediatric thyroid carcinoma. Journal of Radiation Research 2021 62(Supplement 1) i71–i77. (https://doi.org/10.1093/jrr/rraa096)
- 20↑
Faquin WC, Bauer AJ, Nga ME, & Rossi ED. Papillary thyroid carcinoma: endocrine tumors, thyroid epithelial tumors. In World Health Organization Classification of Tumours Editorial Board, Pediatric Tumors. Lyon (France): International Agency for Research on Cancer 2022. WHO classification of tumors series, 5th ed.; vol.7. Available at: https://tumourclassification.iarc.who.int/chaptercontent/44/315
- 21↑
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014 159 676–690. (https://doi.org/10.1016/j.cell.2014.09.050)
- 22↑
Cibas ES, & Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017 27 1341–1346. (https://doi.org/10.1089/thy.2017.0500)
- 23↑
Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, et al.8th edition of the AJCC/TNM staging system of thyroid cancer: What to expect (ITCO#2). Endocrine-Related Cancer . 2018 25 L7–L11. (https://doi.org/10.1530/ERC-17-0453)
- 24↑
Chang F, Lin F, Cao K, Surrey LF, Aplenc R, Bagatell R, Resnick AC, Santi M, Storm PB, Tasian SK, et al. Development and clinical validation of a large fusion gene panel for pediatric cancers. Journal of Molecular Diagnostics 2019 21 873–883. (https://doi.org/10.1016/j.jmoldx.2019.05.006)
- 25↑
Surrey LF, MacFarland SP, Chang F, Cao K, Rathi KS, Akgumus GT, Gallo D, Lin F, Gleason A, Raman P, et al. Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Medicine 2019 11 32. (https://doi.org/10.1186/s13073-019-0644-8)
- 26↑
Mostoufi-Moab S, Labourier E, Sullivan L, LiVolsi V, Li Y, Xiao R, Beaudenon-Huibregtse S, Kazahaya K, Adzick NS, Baloch Z, et al.Molecular testing for oncogenic gene alterations in pediatric thyroid lesions. Thyroid 2018 28 60–67. (https://doi.org/10.1089/thy.2017.0059)
- 27↑
Qiagen OneStep RT-PCR Handbook 2012. Available at: https://www.qiagen.com/us/resources/download.aspx?id=57743726-84e1-423a-9d8f-a3fa89bbe7eb&lang=en
- 28↑
Bauer AJ. Pediatric thyroid cancer: genetics, therapeutics and outcome. Endocrinology and Metabolism Clinics of North America 2020 49 589–611. (https://doi.org/10.1016/j.ecl.2020.08.001)
- 29↑
Potter SL, Reuther J, Chandramohan R, Gandhi I, Hollingsworth F, Sayeed H, Voicu H, Kakkar N, Baksi KS, Sarabia SF, et al.Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma. Pediatric Blood and Cancer 2021 68 e28741. (https://doi.org/10.1002/pbc.28741)
- 30↑
Kleinau G, & Vassart G. TSH receptor mutations and diseases. In Endotext. Eds Feingold KR, Anawalt B, Boyce A, et al.South Dartmouth (MA) 2000. Available at: https://www.ncbi.nlm.nih.gov/books/NBK279140/
- 31↑
R: A Language and Environment for Statistical Computing. Vienna, Austria 2021. Available at: https://www.R-project.org/.
- 32↑
R Studio: Integrated Development Environment for R. Boston, MA 2021. Available at: http://www.rstudio.com/.
- 33↑
Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A, Henry L, Hester J, et al. Welcome to the Tidyverse. Journal of Open Source Software 2019 4. (https://doi.org/10.21105/joss.01686)
- 34↑
Samuels SL, Surrey LF, Hawkes CP, Amberge M, Mostoufi-Moab S, Langer JE, Adzick NS, Kazahaya K, Bhatti T, Baloch Z, et al. Characteristics of follicular variant papillary thyroid carcinoma in a pediatric cohort. Journal of Clinical Endocrinology and Metabolism 2018 103 1639–1648. (https://doi.org/10.1210/jc.2017-02454)
- 35↑
Halada S, Baran JA, Bauer AJ, Ricarte-Filho JC, Isaza A, Patel T, Franco AT, Mostoufi-Moab S, Adzick NS, Kazahaya K, et al.Clinicopathologic characteristics of pediatric follicular variant of papillary thyroid carcinoma subtypes: A retrospective cohort study. Thyroid 2022 32 1353–1361. (https://doi.org/10.1089/thy.2022.0239)
- 36↑
Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, et al. EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. Cancer Discovery 2019 9 264–281. (https://doi.org/10.1158/2159-8290.CD-18-0606)
- 37↑
Baran JA, Halada S, Bauer AJ, Ricarte-Filho JC, Isaza A, Surrey LF, McGrath C, Bhatti T, Jalaly J, Mostoufi-Moab S, et al.Indeterminate thyroid fine-needle aspirations in pediatrics: exploring the clinicopathologic features and utility of molecular profiling. Hormone Research in Paediatrics 2022 95 430–441. (https://doi.org/10.1159/000526116)
- 38↑
Pekova B, Dvorakova S, Sykorova V, Vacinova G, Vaclavikova E, Moravcova J, Katra R, Vlcek P, Sykorova P, Kodetova D, et al. Somatic genetic alterations in a large cohort of pediatric thyroid nodules. Endocrine Connections 2019 8 796–805. (https://doi.org/10.1530/EC-19-0069)
- 39↑
Kakarmath S, Heller HT, Alexander CA, Cibas ES, Krane JF, Barletta JA, Lindeman NI, Frates MC, Benson CB, Gawande AA, et al.Clinical, sonographic, and pathological characteristics of RAS-positive versus BRAF-positive thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2016 101 4938–4944. (https://doi.org/10.1210/jc.2016-2620)
- 40↑
Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, & Sponziello M. Update on fundamental mechanisms of thyroid cancer. Frontiers in Endocrinology (Lausanne) 2020 11 102. (https://doi.org/10.3389/fendo.2020.00102)
- 41↑
Singh A, Ham J, Po JW, Niles N, Roberts T, & Lee CS. The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy. Cells 2021 10. (https://doi.org/10.3390/cells10051082)
- 42↑
Jeon MJ, Kim YN, Sung TY, Hong SJ, Cho YY, Kim TY, Shong YK, Kim WB, Kim SW, Chung JH, et al.Practical initial risk stratification based on lymph node metastases in pediatric and adolescent differentiated thyroid cancer. Thyroid 2018 28 193–200. (https://doi.org/10.1089/thy.2017.0214)
- 43↑
Sugino K, Nagahama M, Kitagawa W, Ohkuwa K, Uruno T, Matsuzu K, Suzuki A, Tomoda C, Hames KY, Akaishi J, et al.Risk stratification of pediatric patients with differentiated thyroid cancer: is total thyroidectomy necessary for patients at any risk? Thyroid 2020 30 548–556. (https://doi.org/10.1089/thy.2019.0231)
